By Matteo Castia

Pharmaceutical group AstraZeneca PLC said Friday that its Farxiga drug to treat chronic kidney disease has been granted the breakthrough therapy designation by the U.S. Food and Drugs Administration.

Farxiga demonstrated the effect of reducing the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in a phase 3 clinical trial.

The breakthrough therapy designation is a status the FDA grants to accelerate the development and regulatory review of potential new medicines that are intended to treat a serious condition and address a significant unmet medical need.

Write to Matteo Castia at matteo.castia@dowjones.com

(END) Dow Jones Newswires

October 02, 2020 02:26 ET (06:26 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more AstraZeneca Charts.